Health CuriosityRECITENCT07613853
The Return of Cardiovascular Information Trial (RECITE)
A study testing Coarse health result information presentation and Granular health risk information presentation in people with Health Curiosity and Cardiovascular Health Risk Communication, run by University of Texas Southwestern Medical Center at 1 site in United States.
Trial summary
The goal of this behavioral interventional trial is to determine how best to communicate personalized cardiovascular risk information and support behavior change among participants enrolled in the Dallas Heart Study (DHS) cohort. Read more about this study
- Who is it for?
- Ages 35 years and olderHealthy volunteers can take part
- Conditions the study is for
- Health Curiosity, Cardiovascular Health Risk Communication
- What is being tested?
- Coarse health result information presentation and Granular health risk information presentation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,500 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Apr 2026to Aug 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Attendance of the Dallas Heart Study-4 clinical visit
- Participant confirms ability and willingness to utilize short links/QR codes during clinical visit
Who cannot join
- Did not attend the Dallas Heart Study-4 clinical visit
- Did not confirm ability and willingness to utilize short links/QR codes
- Participants for whom a PREVENT-CVD score cannot be calculated (those who did not complete a laboratory collection, and/or height/weight measurements [for BMI calculation]), and/or BP assessment, and/or did not complete the medical history questionnaire)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UT Southwestern Medical Center
Dallas, Texas, 75390
Deepa Raj
About this study
The goal of this behavioral interventional trial is to determine how best to communicate personalized cardiovascular risk information and support behavior change among participants enrolled in the Dallas Heart Study (DHS) cohort. The main questions it aims to answer are:
- What are the effects of presenting health information in a coarse vs. granular manner? (This question will be measured by randomizing participants to two groups: one group will get a cover letter with their health information communicated in a more detailed manner, while another group will receive a cover letter which presents their health information in a coarse manner. Two letters will be sent containing the same information regarding their results. 4 months after the second letter, participants will be asked about changes made for their health after receiving the letter)
- How curious are people about bettering their health after being presented their health information? (This question will be measured by placing QR codes linking educational health videos on each cover letter. Each letter will be sent twice with exactly the same health information but with new QR (Quick Response) codes. QR code use will be tracked by the study staff)
Read more
Researchers will assess whether participants who received different style letters had different responses to their health behaviors and medication afterward and will measure this with a follow-up phone call. Researchers will also assess the use of QR codes showing health-related videos (about physical activity, heart-healthy diet, diabetes medication, statin medication) by sending out two different letters with the same health information and format, but with different QR code-linked videos.
Participants will:
- Receive two letters in the mail, 4 weeks apart, containing their results from the Dallas Heart Study's 4th visit. The cover letter for this report will be randomized and will contain coarse vs. granular presentations of the participant's heart health risk.
- Receive a follow up call after 4 months to assess: whether they received the letter, whether they understood the information provided, whether they made any health changes after receiving the letter, whether they saw a healthcare provider after receiving the letter, whether the letter prompted a new diagnosis by a doctor, and whether the participant made any medication changes after the letter.
Read the detailed description
The Return of Cardiovascular Information Trial (RECITE) is a multi-factorial, adaptive randomized behavioral intervention trial which aims to determine how best to communicate personalized cardiovascular risk information and support behavior change among participants attending the Dallas Heart Study (DHS) fourth visit (DHS-4). This embedded behavioral intervention trial will evaluate two independent intervention components-risk information presentation and personalized action-planning support-to identify communication strategies that most effectively motivate and sustain healthy behavior change. The randomized intervention will be receipt of one of two different cover letter templates for the participant post-visit return-of-results letter.
Intervention Components:
The two primary treatment arms differ only in how one's health data measured during the DHS clinic visit are presented in the cover letter. Each cover letter shows the participant's AHA PREVENT (American Heart Association Predicting Risk of Cardiovascular Disease EVENTS) Risk Score results based on assessments performed at the DHS Visit. The risk score representation provides each participant's score compared to the distribution among DHS participants at Visit 3 (2020-2024). Each letter also provides the participant's actual estimated 10-year CVD (Cardiovascular Disease) risk based on the PREVENT Risk Score. To evaluate whether simplified (coarse) or detailed (fine) presentation of risk information better motivates behavior change, participants will be randomized to template cover letters presenting summary risk information as either:
- Arm 1, Coarse Risk Format: Participants receive the standard DHS-4 result report supplemented with visually intuitive risk indicators-such as color-coded categories (green = low risk, red = high risk) and representation of score in a histogram-for outcomes including heart attack, stroke, and diabetes.
- Arm 2, Fine Risk Format: Participants receive the same standard results report, but with precise numerical exact numerical percentile. (e.g., "Your risk of an adverse heart event is higher than 72 percent of DHS participants.") Instead of categorical color cues, there will be a line underlining the risk number that ranges from red "100" to green "0".
Each participant's result letter will be sent to them twice, initially approximately 8 weeks after their DHS Visit 4, and a second time 12 weeks after their visit. All participants will otherwise receive the same clinical test results and observational summaries, preceded by a cover letter, to ensure consistency with standard DHS return-of-results practices.
Each cover letter will also include text recommending that participants view a set of short, publicly available educational YouTube videos, published by reputable health sources such as the American Heart Association and Mayo Clinic, related to heart health and lifestyle behaviors. These recommendations will appear immediately above the video links. Each participant's cover letter, printed or emailed and irrespective of study arm, will have QR codes/short links to the educational videos as described below. The information will be identical for each participant, but the order in which these links are displayed in each cover letter will be randomized to reduce position bias/primacy effect. Each video link will be embedded as a unique URL (Uniform Resource Locator) tied to the participant's de-identified study ID (Identifier), which will allow the study to capture link clicks. Different QR codes/short-links will be provided in the cover letter to the first mailing (8 weeks after visit) and the second mailing (12 weeks after the visit).
Each video delivers practical, actionable guidance, such as:
- How to plan and structure daily routines to increase physical activity
- How to adopt and sustain healthy eating patterns
- Educational information regarding the following medication categories: diabetic medication, hypertension medication, and medication for high cholesterol.
Each participant will also get a follow-up phone call 16 weeks after their DHS study visit. The following questions will be asked:
- Did you get the full results report of your DHS visit? (Yes/No)
- If no, stop survey, ask participant "would you like us to resend it?" If yes, then we resend (after confirming preferred method/contact info)
- If yes, then continue with questions
- Did you understand the information provided to you? (Yes/No/I don't know/Refused)
- Did you make any health changes after receiving your results? (Yes/No/I don't know/Refused)
- If yes, what change did you make? (Exercise, diet, other (free text))
- Did the results report prompt a visit to your / healthcare provider? (Yes/No/I don't know/Refused)
- Did the results report prompt a new diagnosis of hypertension, diabetes, high cholesterol, or another condition by your healthcare provider? (Yes/No/I don't know/Refused)
- If yes, which? Check as many as apply: HTN (Hypertension), diabetes, high cholesterol, or other (free text)
- Were there any changes made to your medication as a result? (Yes/no/I don't know/refused)
Each subject will be identified solely by their pre-established and de-identified Dallas Heart Study (DHS) study ID, and no PHI (Protected Health Information) will be utilized for this clinical trial. Each unique, de-identified participant ID will be linked to a unique, de-identified QR code and short link created using GitHub Enterprise secure software and internal tools. We track participant engagement through website clicks using a simple web-based system (GitHub + Google Sheets) to record when a selection of publicly available educational YouTube videos is accessed. Each video link directs participants to a secure webpage hosted in a GitHub repository and served via GitHub Pages, a widely used academic and open-source static web hosting service. Specifically, GitHub maintains a repository of static (fixed and unedited) HTML (HyperText Markup Language) files, which are made publicly accessible on the internet as individual web links through GitHub Pages. Each file will correspond to each participant's de-identified study ID and video, each containing a small JavaScript component. This allows the links to be shared with participants either as QR codes or as URLs to directly type into a web browser. When a participant accesses a link, the system records minimal metadata (de-identified study ID, video identifier, and timestamp) and then immediately redirects the participant to the intended video content. Click metadata is transmitted securely and in real-time using encrypted HTTPS (HyperText Transfer Protocol Secure) connections to a Google-hosted secure web app (via Google Apps Script), which writes the de-identified information to a private Google Sheet accessible only to authorized study personnel. We systematically create HTML files and QR codes for each HTML web link using Python libraries and each participant's de-identified study ID only. No protected health information, HIPAA identifiers, IP (Internet Protocol) addresses, or device-level data are collected or stored as any part of this process. The use of this system is considered minimal risk, as it does not involve activity beyond standard web navigation and collects only limited, non-identifiable engagement data. Participants do not have access to the underlying code, data storage location, or logs, and cannot modify or view collected data. The system does not install software, use cookies, or track user behavior beyond the single link-click event.
- Being tested
- Coarse health result information presentation, Granular health risk information presentation
- Keywords
- Health information communication, Behavioral intervention trial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coarse health result information presentationBehavioural
Participants are randomized to 1 of 2 cover-letter formats accompanying standard Dallas Heart Study (DHS) results. Both include AHA PREVENT Risk Score results from the DHS visit, comparison with the DHS Visit 3 distribution, and estimated 10-year CVD risk. Arm 1 (Coarse): color-coded risk categories/histogram for heart attack, stroke, and diabetes. Arm 2 (Fine/Granular): exact percentile/numerical risk with a red-to-green scale. Letters are sent at 8 and 12 weeks post-visit. All letters also recommend identical publicly available educational videos on physical activity, diet, and diabetes, hypertension, and cholesterol medications; link order is randomized. Unique de-identified QR codes/URLs track clicks only. At 16 weeks, participants receive follow-up calls about receipt, understanding, behavior change, healthcare visits/new diagnoses, and medication changes. Only de-identified DHS IDs are used; no PHI is collected.
Granular health risk information presentationBehavioural
Participants are randomized to 1 of 2 cover-letter formats accompanying standard Dallas Heart Study (DHS) results. Both include AHA PREVENT Risk Score results from the DHS visit, comparison with the DHS Visit 3 distribution, and estimated 10-year CVD risk. Arm 1 (Coarse): color-coded risk categories/histogram for heart attack, stroke, and diabetes. Arm 2 (Fine/Granular): exact percentile/numerical risk with a red-to-green scale. Letters are sent at 8 and 12 weeks post-visit. All letters also recommend identical publicly available educational videos on physical activity, diet, and diabetes, hypertension, and cholesterol medications; link order is randomized. Unique de-identified QR codes/URLs track clicks only. At 16 weeks, participants receive follow-up calls about receipt, understanding, behavior change, healthcare visits/new diagnoses, and medication changes. Only de-identified DHS IDs are used; no PHI is collected.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1, Coarse Health Risk Format | Experimental | Arm 1, Coarse Risk Format: Participants receive the standard Dallas Heart Study results report with a cover letter demonstrating their AHA-PREVENT 10-year CVD risk score visually intuitive risk indicators-such as color-coded categories (green = low risk, red = high risk) and representation of score in a histogram-for outcomes including heart attack, stroke, and diabetes. Receives: Behavioral: Coarse health result information presentation |
| Arm 2, Granular Health Risk Format | Experimental | Arm 2, Fine Risk Format: Participants receive the standard Dallas Heart Study results report with a cover letter demonstrating their AHA-PREVENT 10-year CVD risk score but with precise numerical exact numerical percentile. (e.g., "Your risk of an adverse heart event is higher than 72 percent of DHS participants.") Instead of categorical color cues, there will be a line underlining the risk number that ranges from red "100" to green "0". Receives: Behavioral: Granular health risk information presentation |
What is being measured
The primary outcome is the main question the study is designed to answer.
QR Code use for Educational Health Videos
Number of clicks per link/QR code in the 3 weeks after Result Letter #1 sent
Measured: 3 weeks after first health results letter is sent
Change in Educational Health Video Engagement
Change in number of clicks per link/QR code in the 3 weeks after Result Letter #2
Measured: 3 weeks following the second result letter is sent
Secondary outcomes (1)
Self-reported health behavior changes
- Self-reported behavior changes assessed at the 4 month (16 week) follow up phone call:
- Participant self-report of seeing physician based off of health results
- Participant self-report of making lifestyle changes based on their delivered health results
Measured: 16 weeks after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2026
- Study start22 Apr 2026
- Primary completionApr 2028 (estimated)
- Study completionAug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Health CuriosityStudies of the same condition, open and under way.
- More trials run by University of Texas Southwestern Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The two primary treatment arms differ only in how one's health data measured during the DHS clinic visit are presented in the cover letter. Each cover letter shows the participant's AHA PREVENT Risk Score results based on assessments performed at the DHS Visit. The risk score representation provides each participant's score compared to the distribution among DHS participants at Visit 3 (2020-2024). Each letter also provides the participant's actual estimated 10-10-year CVD risk based on the PREVENT Risk Score. To evaluate whether simplified (coarse) or detailed (fine) presentation of risk information better motivates behavior change, participants will be randomized to template cover letters presenting summary risk information as either: Coarse Risk Format (as color-coded categories (green = low risk, red = high risk) and representation of score in a histogram) or Granular risk format (precise numerical exact numerical percentile).
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Johns Hopkins University
- Responsible party
- Principal investigator, Amil Shah, University of Texas Southwestern Medical Center
- Investigators
- Amil M Shah, MD, MPH, Principal investigator, University of Texas Southwestern Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07613853
- Sponsor's protocol ID
- STU20260475
- Other IDs
- 1R01DK145081-01
- Acronym
- RECITE
- Status last verified
- Jun 2026
- First submitted
- 21 May 2026
- Last updated
- 15 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Return of Cardiovascular Information Trial (RECITE)
- ClinicalTrials.gov ID
- NCT07613853
- Acronym / sponsor ID
- RECITE / STU20260475
- Keywords
- Health information communication, Behavioral intervention trial
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- University of Texas Southwestern Medical CenterUniversity, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Johns Hopkins University
- Study start
- 22 Apr 2026 (actual)
- Primary completion
- Apr 2028 (estimated)
- Study completion
- Aug 2028 (estimated)
- First posted
- 29 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this behavioral interventional trial is to determine how best to communicate personalized cardiovascular risk information and support behavior change among participants enrolled in the Dallas Heart Study (DHS) cohort. The main questions it aims to answer are:
- What are the effects of presenting health information in a coarse vs. granular manner? (This question will be measured by randomizing participants to two groups: one group will get a cover letter with their health information communicated in a more detailed manner, while another group will receive a cover letter which presents their health information in a coarse manner. Two letters will be sent containing the same information regarding their results. 4 months after the second letter, participants will be asked about changes made for their health after receiving the letter)
- How curious are people about bettering their health after being presented their health information? (This question will be measured by placing QR codes linking educational health videos on each cover letter. Each letter will be sent twice with exactly the same health information but with new QR (Quick Response) codes. QR code use will be tracked by the study staff)
Researchers will assess whether participants who received different style letters had different responses to their health behaviors and medication afterward and will measure this with a follow-up phone call. Researchers will also assess the use of QR codes showing health-related videos (about physical activity, heart-healthy diet, diabetes medication, statin medication) by sending out two different letters with the same health information and format, but with different QR code-linked videos.
Participants will:
- Receive two letters in the mail, 4 weeks apart, containing their results from the Dallas Heart Study's 4th visit. The cover letter for this report will be randomized and will contain coarse vs. granular presentations of the participant's heart health risk.
- Receive a follow up call after 4 months to assess: whether they received the letter, whether they understood the information provided, whether they made any health changes after receiving the letter, whether they saw a healthcare provider after receiving the letter, whether the letter prompted a new diagnosis by a doctor, and whether the participant made any medication changes after the letter.
Detailed description
The Return of Cardiovascular Information Trial (RECITE) is a multi-factorial, adaptive randomized behavioral intervention trial which aims to determine how best to communicate personalized cardiovascular risk information and support behavior change among participants attending the Dallas Heart Study (DHS) fourth visit (DHS-4). This embedded behavioral intervention trial will evaluate two independent intervention components-risk information presentation and personalized action-planning support-to identify communication strategies that most effectively motivate and sustain healthy behavior change. The randomized intervention will be receipt of one of two different cover letter templates for the participant post-visit return-of-results letter.
Intervention Components:
The two primary treatment arms differ only in how one's health data measured during the DHS clinic visit are presented in the cover letter. Each cover letter shows the participant's AHA PREVENT (American Heart Association Predicting Risk of Cardiovascular Disease EVENTS) Risk Score results based on assessments performed at the DHS Visit. The risk score representation provides each participant's score compared to the distribution among DHS participants at Visit 3 (2020-2024). Each letter also provides the participant's actual estimated 10-year CVD (Cardiovascular Disease) risk based on the PREVENT Risk Score. To evaluate whether simplified (coarse) or detailed (fine) presentation of risk information better motivates behavior change, participants will be randomized to template cover letters presenting summary risk information as either:
- Arm 1, Coarse Risk Format: Participants receive the standard DHS-4 result report supplemented with visually intuitive risk indicators-such as color-coded categories (green = low risk, red = high risk) and representation of score in a histogram-for outcomes including heart attack, stroke, and diabetes.
- Arm 2, Fine Risk Format: Participants receive the same standard results report, but with precise numerical exact numerical percentile. (e.g., "Your risk of an adverse heart event is higher than 72 percent of DHS participants.") Instead of categorical color cues, there will be a line underlining the risk number that ranges from red "100" to green "0".
Each participant's result letter will be sent to them twice, initially approximately 8 weeks after their DHS Visit 4, and a second time 12 weeks after their visit. All participants will otherwise receive the same clinical test results and observational summaries, preceded by a cover letter, to ensure consistency with standard DHS return-of-results practices.
Each cover letter will also include text recommending that participants view a set of short, publicly available educational YouTube videos, published by reputable health sources such as the American Heart Association and Mayo Clinic, related to heart health and lifestyle behaviors. These recommendations will appear immediately above the video links. Each participant's cover letter, printed or emailed and irrespective of study arm, will have QR codes/short links to the educational videos as described below. The information will be identical for each participant, but the order in which these links are displayed in each cover letter will be randomized to reduce position bias/primacy effect. Each video link will be embedded as a unique URL (Uniform Resource Locator) tied to the participant's de-identified study ID (Identifier), which will allow the study to capture link clicks. Different QR codes/short-links will be provided in the cover letter to the first mailing (8 weeks after visit) and the second mailing (12 weeks after the visit).
Each video delivers practical, actionable guidance, such as:
- How to plan and structure daily routines to increase physical activity
- How to adopt and sustain healthy eating patterns
- Educational information regarding the following medication categories: diabetic medication, hypertension medication, and medication for high cholesterol.
Each participant will also get a follow-up phone call 16 weeks after their DHS study visit. The following questions will be asked:
- Did you get the full results report of your DHS visit? (Yes/No)
- If no, stop survey, ask participant "would you like us to resend it?" If yes, then we resend (after confirming preferred method/contact info)
- If yes, then continue with questions
- Did you understand the information provided to you? (Yes/No/I don't know/Refused)
- Did you make any health changes after receiving your results? (Yes/No/I don't know/Refused)
- If yes, what change did you make? (Exercise, diet, other (free text))
- Did the results report prompt a visit to your / healthcare provider? (Yes/No/I don't know/Refused)
- Did the results report prompt a new diagnosis of hypertension, diabetes, high cholesterol, or another condition by your healthcare provider? (Yes/No/I don't know/Refused)
- If yes, which? Check as many as apply: HTN (Hypertension), diabetes, high cholesterol, or other (free text)
- Were there any changes made to your medication as a result? (Yes/no/I don't know/refused)
Each subject will be identified solely by their pre-established and de-identified Dallas Heart Study (DHS) study ID, and no PHI (Protected Health Information) will be utilized for this clinical trial. Each unique, de-identified participant ID will be linked to a unique, de-identified QR code and short link created using GitHub Enterprise secure software and internal tools. We track participant engagement through website clicks using a simple web-based system (GitHub + Google Sheets) to record when a selection of publicly available educational YouTube videos is accessed. Each video link directs participants to a secure webpage hosted in a GitHub repository and served via GitHub Pages, a widely used academic and open-source static web hosting service. Specifically, GitHub maintains a repository of static (fixed and unedited) HTML (HyperText Markup Language) files, which are made publicly accessible on the internet as individual web links through GitHub Pages. Each file will correspond to each participant's de-identified study ID and video, each containing a small JavaScript component. This allows the links to be shared with participants either as QR codes or as URLs to directly type into a web browser. When a participant accesses a link, the system records minimal metadata (de-identified study ID, video identifier, and timestamp) and then immediately redirects the participant to the intended video content. Click metadata is transmitted securely and in real-time using encrypted HTTPS (HyperText Transfer Protocol Secure) connections to a Google-hosted secure web app (via Google Apps Script), which writes the de-identified information to a private Google Sheet accessible only to authorized study personnel. We systematically create HTML files and QR codes for each HTML web link using Python libraries and each participant's de-identified study ID only. No protected health information, HIPAA identifiers, IP (Internet Protocol) addresses, or device-level data are collected or stored as any part of this process. The use of this system is considered minimal risk, as it does not involve activity beyond standard web navigation and collects only limited, non-identifiable engagement data. Participants do not have access to the underlying code, data storage location, or logs, and cannot modify or view collected data. The system does not install software, use cookies, or track user behavior beyond the single link-click event.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- The two primary treatment arms differ only in how one's health data measured during the DHS clinic visit are presented in the cover letter. Each cover letter shows the participant's AHA PREVENT Risk Score results based on assessments performed at the DHS Visit. The risk score representation provides each participant's score compared to the distribution among DHS participants at Visit 3 (2020-2024). Each letter also provides the participant's actual estimated 10-10-year CVD risk based on the PREVENT Risk Score. To evaluate whether simplified (coarse) or detailed (fine) presentation of risk information better motivates behavior change, participants will be randomized to template cover letters presenting summary risk information as either: Coarse Risk Format (as color-coded categories (green = low risk, red = high risk) and representation of score in a histogram) or Granular risk format (precise numerical exact numerical percentile).
| Arm | Type | Receives |
|---|---|---|
| Arm 1, Coarse Health Risk Format | Experimental | Behavioral: Coarse health result information presentationArm 1, Coarse Risk Format: Participants receive the standard Dallas Heart Study results report with a cover letter demonstrating their AHA-PREVENT 10-year CVD risk score visually intuitive risk indicators-such as color-coded categories (green = low risk, red = high risk) and representation of score in a histogram-for outcomes including heart attack, stroke, and diabetes. |
| Arm 2, Granular Health Risk Format | Experimental | Behavioral: Granular health risk information presentationArm 2, Fine Risk Format: Participants receive the standard Dallas Heart Study results report with a cover letter demonstrating their AHA-PREVENT 10-year CVD risk score but with precise numerical exact numerical percentile. (e.g., "Your risk of an adverse heart event is higher than 72 percent of DHS participants.") Instead of categorical color cues, there will be a line underlining the risk number that ranges from red "100" to green "0". |
Who may qualify
- Ages
- 35 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Attendance of the Dallas Heart Study-4 clinical visit
- Participant confirms ability and willingness to utilize short links/QR codes during clinical visit
Key exclusion criteria (3 listed)
- Did not attend the Dallas Heart Study-4 clinical visit
- Did not confirm ability and willingness to utilize short links/QR codes
- Participants for whom a PREVENT-CVD score cannot be calculated (those who did not complete a laboratory collection, and/or height/weight measurements [for BMI calculation]), and/or BP assessment, and/or did not complete the medical history questionnaire)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coarse health result information presentationParticipants are randomized to 1 of 2 cover-letter formats accompanying standard Dallas Heart Study (DHS) results. Both include AHA PREVENT Risk Score results from the DHS visit, comparison with the DHS Visit 3 distribution, and estimated 10-year CVD risk. Arm 1 (Coarse): color-coded risk categories/histogram for heart attack, stroke, and diabetes. Arm 2 (Fine/Granular): exact percentile/numerical risk with a red-to-green scale. Letters are sent at 8 and 12 weeks post-visit. All letters also recommend identical publicly available educational videos on physical activity, diet, and diabetes, hypertension, and cholesterol medications; link order is randomized. Unique de-identified QR codes/URLs track clicks only. At 16 weeks, participants receive follow-up calls about receipt, understanding, behavior change, healthcare visits/new diagnoses, and medication changes. Only de-identified DHS IDs are used; no PHI is collected. | Behavioural | Arm 1, Coarse Health Risk Format |
| Granular health risk information presentationParticipants are randomized to 1 of 2 cover-letter formats accompanying standard Dallas Heart Study (DHS) results. Both include AHA PREVENT Risk Score results from the DHS visit, comparison with the DHS Visit 3 distribution, and estimated 10-year CVD risk. Arm 1 (Coarse): color-coded risk categories/histogram for heart attack, stroke, and diabetes. Arm 2 (Fine/Granular): exact percentile/numerical risk with a red-to-green scale. Letters are sent at 8 and 12 weeks post-visit. All letters also recommend identical publicly available educational videos on physical activity, diet, and diabetes, hypertension, and cholesterol medications; link order is randomized. Unique de-identified QR codes/URLs track clicks only. At 16 weeks, participants receive follow-up calls about receipt, understanding, behavior change, healthcare visits/new diagnoses, and medication changes. Only de-identified DHS IDs are used; no PHI is collected. | Behavioural | Arm 2, Granular Health Risk Format |
Primary outcome
QR Code use for Educational Health Videos
Time frame: 3 weeks after first health results letter is sent
Number of clicks per link/QR code in the 3 weeks after Result Letter #1 sent
Change in Educational Health Video Engagement
Time frame: 3 weeks following the second result letter is sent
Change in number of clicks per link/QR code in the 3 weeks after Result Letter #2
1 secondary outcome
Self-reported health behavior changes
Time frame: 16 weeks after randomization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amil M Shah, MD, MPH principal investigator
University of Texas Southwestern Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Coarse health result information presentation and Granular health risk information presentation in people with Health Curiosity and Cardiovascular Health Risk Communication, run by University of Texas Southwestern Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Deepa Raj, BA, MPH (214-648-9256, deepa.raj@utsouthwestern.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
QR Code use for Educational Health Videos (time frame: 3 weeks after first health results letter is sent). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026.